First leukemia patient dosed with SMART101
Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell.
The first enrolled patient received a SMART101 injection in December 2022; no related adverse events have been reported.
Karine Rossignol, chief executive officer of SmartImmune, said: “We are excited to sponsor this pioneering trial. Accelerated reconstitution of a full polyclonal T-cell repertoire after stem cell transplantation could improve both quality of life and clinical outcomes for patients with acute leukemia, and we look forward to releasing more data as the trial progresses.”
Researchers think SMART101 may reduce the risk of infection by speeding the production of donor T cells after a T-cell depleted transplant. These cells cannot cause GvHD because they mature in the body of the transplant recipient, but they can potentially reduce infection.
https://www.labiotech.eu/trends-news/first-leukemia-patient-dosed-smart101/
ارسال به دوستان